EUVIMEDEUVIMED entdecken
Crossref

Exploring the Role of Novel N (4) Substituted 5,7‐Dibromoisatin Thiosemicarbazones in Modulating PTOV1 Activity for Therapeutic Relevance in Breast Cancer

Piyush Kumar iD, Upendra Chaudhary iD, Kuldeep Mahiya iD, Anshuman Chandra, Vijay Kumar Goel, Yuba Raj Pokharel iD, Paras Nath Yadav iD

Drug Development Research · 2026-05 · 87 (3)

DOI: 10.1002/ddr.70306 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Development Research, online erschienen am 10.05.2026. Verfasst von Piyush Kumar und 6 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Life Sciences and Biotechnology, South Asian University, Maidan Garhi, New Delhi, India. Hauptthemen laut MEDLINE: Thiosemicarbazones, Breast Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 105 Literaturangaben. Gefördert von: Nepal Academy of Science and Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We herein report the synthesis, and antiproliferative evaluation of a novel series of N(4)‐substituted 5,7‐dibromoisatin thiosemicarbazones (TSCs). Structure and activity based approach was used to synthesize derivatives: N(4)‐pyrrolidinyl (L1), N(4)‐piperidinyl (L2), N(4)‐morpholinyl (L3), N(4)‐methyl (L4), and N(4)‐ethyl (L5). The compounds were characterized by elemental analysis, FTIR, 1 H NMR, 13 C NMR, UV‐Vis spectroscopy, HRMS and single crystal X‐ray analysis. The antiproliferative activity of the synthesized TSCs was evaluated in a dose‐dependent manner against breast (MCF‐7, MDA‐MB‐231), skin (A431), lung (A549, NCI‐H460), and prostate (PC3) cancer cell lines. L3 and L5 exhibited enhanced cytotoxicity in the low micromolar range of IC 50 ; 1.16–2.47 µM. Notably, L5 showed superior potency in MCF‐7 cells with IC 50 ; 1.16 µM compared to the FDA‐approved thiosemicarbazone Triapine with IC 50 ; 4.27 µM, while displaying minimal toxicity toward non‐tumorigenic MCF‐10a breast epithelial cells with selectivity index > 86.20, consistent with ADMET predictions. Molecular docking and molecular dynamics simulations demonstrated stronger binding affinity and greater complex stability of L5 with PTOV1 compared to the FDA approved drug Lenalidomide, supporting L5 drug likeness and therapeutic potential. Mechanistic investigations through functional assays like crystal violet assays, flow cytometry, immunoblotting, and microscopy revealed that L5 induces G0/G1 cell‐cycle arrest, suppresses cell migration, invasion, colony formation, 3D spheroid growth, and promotes apoptotic cell death in MCF‐7. Western blot analysis provided direct mechanistic evidence that L5 downregulates PTOV1 expression, leading to reduced phosphorylation of AKT1/2/3 and c‐Jun, reduced β‐catenin nuclear translocation, and decreased MMP‐2 expression. L5 enhanced H2AX phosphorylation, suppressed PARP and BCL‐XL levels, and increased active caspase‐3 driving L5 induced apoptosis. This study identifies L5 as a potent anticancer agent in breast cancer, acting through modulation of the PTOV1‐AKT‐β‐catenin signaling axis, and highlights PTOV1 as a promising therapeutic target.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ThiosemicarbazonesBreast NeoplasmsAntineoplastic AgentsHumansFemaleCell Line, TumorCell ProliferationStructure-Activity RelationshipMolecular Docking SimulationApoptosisMCF-7 Cells

Stichwörter der Autor:innen

5,7‐Dibromoisatin‐TSCAKT1/2/3anticancer propertiesbreast cancermolecular screeningthiosemicarbazonesγH2AX

Substanzen

ThiosemicarbazonesAntineoplastic Agents

Autor:innen und Institutionen

  • Faculty of Life Sciences and Biotechnology, South Asian University, Maidan Garhi, New Delhi, India.
  • Central Department of Chemistry, Tribhuvan University, Kirtipur, Kathmandu, Nepal.
  • Department of Chemistry, F G M Government College, Adampur, Mandi Adampur, Hisar, Haryana, India.
  • School of Physical Sciences, Jawaharlal Nehru University, New Delhi, India.
  • Research Center for Applied Science and Technology, Tribhuvan University, Kirtipur, Kathmandu, Nepal.

ORCID-Profile: Piyush Kumar, Upendra Chaudhary, Kuldeep Mahiya, Yuba Raj Pokharel, Paras Nath Yadav

Förderung

  • Nepal Academy of Science and Technology

Zitieren

APA

Kumar, P., Chaudhary, U., Mahiya, K., Chandra, A., Goel, V. K., Pokharel, Y. R., & Yadav, P. N. (2026). Exploring the Role of Novel N (4) Substituted 5,7‐Dibromoisatin Thiosemicarbazones in Modulating PTOV1 Activity for Therapeutic Relevance in Breast Cancer. Drug Development Research, 87(3). https://doi.org/10.1002/ddr.70306

Vancouver

Kumar P, Chaudhary U, Mahiya K, Chandra A, Goel VK, Pokharel YR, et al. Exploring the Role of Novel N (4) Substituted 5,7‐Dibromoisatin Thiosemicarbazones in Modulating PTOV1 Activity for Therapeutic Relevance in Breast Cancer. Drug Development Research. 2026;87(3). doi:10.1002/ddr.70306

BibTeX
@article{Kumar2026,
  author = {Kumar, Piyush and Chaudhary, Upendra and Mahiya, Kuldeep and Chandra, Anshuman and Goel, Vijay Kumar and Pokharel, Yuba Raj and Yadav, Paras Nath},
  title = {Exploring the Role of Novel N (4) Substituted 5,7‐Dibromoisatin Thiosemicarbazones in Modulating PTOV1 Activity for Therapeutic Relevance in Breast Cancer},
  journal = {Drug Development Research},
  year = {2026},
  volume = {87},
  number = {3},
  doi = {10.1002/ddr.70306}
}
Kostenlos starten →